Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Ligelizumab 240 mg in Chronic Spontaneous Urticaria (Extension of CQGE031C2201)
jRCT2080223242Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of ligelizumab in chronic idiopathic urticaria (CIU), sponsored by Novartis. Started Jun 2016; status: completed.
02
Drugs
ligelizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2080223242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223242.